Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Drug Profile

Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Alternative Names: Asthma and allergy therapeutics - Spring Bank; Cancer therapeutics - Spring Bank; COPD therapeutics - Spring Bank; SB 11177; SB 11179; SB 11285

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Nucleic acids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cytokine stimulants; Immunomodulators; Interferon stimulants; Pattern recognition receptor agonists; Protein inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 31 Oct 2017 Spring Bank Pharmaceuticals announces intention to submit an IND application and/or a clinical trial application for SB 11285 to the US FDA and/or EMA in mid-2018
  • 31 Oct 2017 Spring Bank Pharmaceuticals plans a phase Ib/II trial of SB 11285 for Liver cancer in the second half of 2018
  • 02 Oct 2017 Pharmacodynamics data from a preclinical study in Cancer released by Spring Bank Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top